Schnitzer TJ, et al. Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee. ACR 2018, abstract L20.
Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken
jun 2018 | Spondyloartritis